Massmedica S.A.
5.36
PLN
-0.02
(-0.37%)
Massmedica S.A.
NEWCONNECT:MSM
(NewConnect)
Recent
price
5.36
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Massmedica S.A. is a Poland-based medical technology and distribution company specializing in the supply, development, and commercialization of advanced medical devices, orthopedic implants, and regenerative medicine solutions. Founded in 2017 and headquartered in Warsaw, Poland, the company operates across Poland and the Central and Eastern European region, catering to public and private hospitals, specialized surgical centers, orthopedic departments, and private healthcare practitioners. Massmedica S.A. is publicly traded on the NewConnect market of the Warsaw Stock Exchange under the ticker MSM. The company operates through two primary commercial divisions, Evo Tested and Forever Young, supported by a specialized research and technology development subsidiary. Its comprehensive product and service portfolio includes: reconstructive orthopedic implants, comprising primary, revision, and oncological hip and knee endoprostheses sourced from international partners such as Corin and Merete; custom patient-specific 3D-printed implants and anatomical models engineered in collaboration with Materialise; trauma osteosynthesis devices, bone fixation screws, and intramedullary nails; bone graft substitutes, surgical biomaterials, and bone cements; regenerative and sports medicine systems, comprising autologous platelet-rich plasma (PRP) separation kits, bone marrow aspirate concentrate (BMAC) systems, and stem cell isolation devices; tissue reconstruction and viscosupplementation therapies, including intra-articular and dermatological hyaluronic acid formulations; orthopedic immobilization devices, including the OPENCAST breathable and waterproof rigid immobilization system; and specialized surgical equipment training, logistical distribution, and clinical advisory services. In recent corporate developments, Massmedica S.A. has executed a strategic transition to expand beyond third-party distribution into proprietary medical robotics and advanced technology manufacturing through its subsidiary, Massmedica Technologie Sp. z o.o. The company completed the development of the functional prototype for its Universal Robotic Surgical Assistant (URSA Minor), designed to assist orthopedic surgeons during arthroplasty procedures, and initiated system validation and clinical trial preparations. To support the global commercialization and production of its robotic and orthopedic portfolio, Massmedica entered into a strategic alliance and letter of intent with Beijing Chunli Zhengda Medical Instrument Co., Ltd. (Chunli) focusing on joint robotic development, mutual licensing, and supply chain cooperation. Furthermore, the company has initiated corporate restructuring and regulatory procedures to transfer its equity listing from the NewConnect multilateral trading facility to the Main Market of the Warsaw Stock Exchange to support its ongoing research, development, and geographical expansion.